Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avanir Pharmaceuticals
Pharmaceutical company president, CEO resigns
June 15th, 2005
Avanir Pharmaceuticals (AVN) announced that Gerald J. Yakatan, PhD, resigned effective May 16, 2005, as Avanir's president and CEO and as a member of its board of directors. Following his resignation, Yakatan will continue on as a consultant to Avanir for 1 year, advising the company on its Neurodex new drug application (NDA). "The board is grateful to Yakatan for his leadership over the past 7 years," said Jonathan Silverstein, a member of Avanir's board of directors. "During his tenure, Avanir was able to obtain U.S. Food & Drug Administration (FDA) approval for Abreva and develop Neurodex through its rolling NDA submission. He...
Source: Physician Law Weekly (2005-06-15)
|
